Updated June 2026  |  Rx.com

You've probably seen the headlines. "$99/month for semaglutide!" "Zepbound starting at $149!" "Medicare now covers Wegovy!"

And then you start digging and discover that the $99 is a starter microdose you'll outgrow in six weeks. The $149 Medicare quote requires prior authorization, a BMI over 30, and a July 2026 launch date. And the $199 Wegovy offer goes up to $349 after your first two fills.

GLP-1 pricing is genuinely confusing — by design. This article cuts through it. We've researched every major pathway: brand-name drugs, compounded options, insurance, Medicare, telehealth platforms, and the introductory-price traps hiding in plain sight. If you're trying to figure out what you'll actually spend each month, this is the guide.

First: What Are GLP-1 Medications?

GLP-1 receptor agonists (glucagon-like peptide-1) are a class of medications originally developed to treat type 2 diabetes. They work by mimicking a gut hormone that signals fullness, slows digestion, and reduces appetite. In weight-loss trials, semaglutide (the active ingredient in Wegovy and Ozempic) helped patients lose 15% of their body weight on average. Tirzepatide (Zepbound, Mounjaro) — a dual GIP/GLP-1 agonist — performed even better, with participants in the SURMOUNT trials losing an average of 20.9% of their body weight.

This efficacy is why roughly 40 million Americans have now used a GLP-1 for weight loss, and why demand is outpacing the ability of most people to afford them.

The Pricing Landscape: Five Very Different Numbers

Before comparing options, understand that there is no single "price" for GLP-1 medications. What you pay depends on which drug, which form (brand-name vs. compounded), how you access it, your insurance status, and which dose you're on. Here are the five distinct pricing realities:

1. Brand-Name List Price (What Almost Nobody Actually Pays)

The manufacturer's list price — also called the wholesale acquisition cost — is the sticker price before any discounts, insurance, or savings programs. As of mid-2026:

Almost no cash-paying consumer pays these prices. They exist primarily as the starting point for insurance negotiations and rebates. But they matter because some uninsured patients — particularly those who don't know their options — do end up paying close to these amounts at a retail pharmacy without a savings program.

2. Brand-Name with Manufacturer Savings Programs

Both Eli Lilly and Novo Nordisk operate direct-to-consumer programs that dramatically undercut their own list prices for cash-paying patients:

• LillyDirect (Zepbound): Cash-paying patients with a valid prescription can access Zepbound vials starting at $299–$449/month depending on dose, down from the list price of over $1,000. Eli Lilly recently lowered these prices further following a federal pricing agreement.
• Novo Nordisk / NovoCare (Wegovy & Ozempic): Cash-paying patients can access Wegovy and Ozempic at $349/month for ongoing fills. New patients get an introductory rate of $199/month for the first two months on the two lowest doses — after which the price steps up to $349.
• GoodRx partnership pricing: Through GoodRx, the lowest doses of Wegovy start at $149/month (introductory), with ongoing fills at $299–$349/month. Zepbound KwikPen starts at $299/month through GoodRx.

3. Compounded Semaglutide and Tirzepatide

Compounded GLP-1 medications are prepared by licensed pharmacies using the same active molecules as brand-name drugs. They became a widespread option during drug shortage periods and are now primarily dispensed through state-licensed 503A pharmacies with individualized prescriptions.

Current compounded pricing ranges:

The cheapest legitimate compounded semaglutide programs cluster around $129–$149/month — but that's typically for the starting 0.25 mg dose, which is below the therapeutic range for most patients. Maintenance doses generally push costs to $199–$299/month. Compounded tirzepatide at therapeutic maintenance runs $299–$399/month at the most competitive flat-rate platforms.

What compounded medications are not: FDA-approved and not therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound. The active molecule is the same, but the compounded version has not gone through FDA's review for safety, efficacy, and manufacturing consistency. This doesn't mean they're unsafe — licensed compounding pharmacies operate under state board and USP standards — but it's a meaningful distinction worth understanding before you start.

4. Telehealth Platforms: The Wild West of Pricing

The telehealth channel is where GLP-1 pricing gets the most confusing — and frankly, where the most deceptive practices have emerged.

The "introductory price" problem: Virtually every telehealth platform advertising a GLP-1 price is showing you a first-month rate. That first month typically covers only the lowest starter dose (0.25 mg for semaglutide, 2.5 mg for tirzepatide). By months 2–4, as your dose titrates up, you're often paying 30–60% more than that headline number. A platform advertising "$99/month" is almost certainly quoting a semaglutide microdose. Their standard injectable at maintenance is three to four times that.

The FTC has noticed. In 2025, the FTC took enforcement action against NextMed for advertising "only $79 for your first month" without disclosing medication costs, lab fees, mandatory membership terms, and early-termination fees. In March 2026, the FDA issued warning letters to more than 30 telehealth companies for misleading compounded GLP-1 marketing.

The membership fee layer: Some platforms charge a separate monthly subscription fee ($49–$149/month) on top of medication costs. Always verify whether the quoted price includes the medication, consultation, and shipping — or whether those are separate line items.

Representative pricing by tier (mid-2026):

• Budget tier ($129–$199/month): Ro, Henry Meds, Shed, and Cora Health offer all-in compounded semaglutide starting around $129–$149/month. No separate membership fee. Async consultations. Price may increase at higher doses.
• Mid tier ($159–$249/month): Found and Noom add video consultations, coaching, or behavioral programming.
• Premium tier ($299+/month): Calibrate and FORM Health include board-certified obesity specialists, metabolic lab panels, and registered dietitians.
• Hims update (2026): Hims has fully exited compounded GLP-1 medications and now operates as an authorized Novo Nordisk distributor selling brand-name Wegovy only.

5. Insurance and Government Programs

Insurance is the single biggest variable in GLP-1 cost. The same medication can cost $25/month with the right coverage or $1,349/month without any.

Employer-sponsored insurance: As of 2025, only about 19% of large employers (200+ workers) cover GLP-1 drugs for weight loss in their largest health plan. For plans that do cover them, prior authorization is nearly universal — typically requiring a BMI ≥ 30, or ≥ 27 with a weight-related comorbidity, plus documentation of prior lifestyle interventions. Co-pays range from $25–$100/month.

Medicare (2026): Traditional Medicare Part D has historically not covered GLP-1 medications for weight loss — only for diabetes or cardiovascular disease. That is changing:

• Medicare GLP-1 Bridge Program (July 1, 2026): Medicare Part D enrollees who qualify can access Wegovy (injectable and oral), Foundayo, or Zepbound KwikPen for a $50/month co-pay. The manufacturer net price under this program is $245/month. Requires prior authorization and must meet BMI and clinical criteria.
• BALANCE Model (2027): The longer-term Medicare coverage framework launches in January 2027. Medicaid coverage begins as early as May 2026 in participating states.

Medicaid: Only 13 states covered GLP-1s for weight loss in adults as of mid-2024. The BALANCE Model may expand this beginning in May 2026, but state participation is not guaranteed. Some states — including Colorado, West Virginia, and North Carolina — have already rolled back or paused GLP-1 coverage due to budget constraints.

The Real Annual Cost: What to Budget

Here's what a year of GLP-1 therapy actually costs across the main pathways for a cash-paying patient who titrates to a therapeutic maintenance dose:

A 2026 modeling study found that annual out-of-pocket costs often exceed $3,000 for cash-paying patients — and reach $4,000 or more at injectable maintenance prices. States with the highest income burden for these drugs are also, notably, the states with the highest obesity rates.

Why Transparent Pricing Matters

The compounding and telehealth markets grew largely because brand-name prices were inaccessible to most people without insurance. That was legitimate — and it served millions of patients who had no other realistic path to treatment.

But the channel also created conditions for pricing confusion to flourish. Teaser rates. Dose-based escalators buried in terms of service. Membership fees that don't show up in the headline number. Multi-month lock-ins disguised as "programs."

At Rx.com, we believe you should know exactly what you'll pay — not on month one at the starting dose, but at month four when you're at a therapeutic level and the bill arrives. Transparent, all-in pricing at every dose tier isn't a marketing position. It's the minimum standard for informed consent.

The Bottom Line: How to Find Your Real Number

1. Check your insurance first. Even if you've assumed your plan doesn't cover GLP-1s, call and ask specifically about weight loss indications. Coverage has expanded. If your plan covers them, the math changes entirely.
2. Compare all-in maintenance prices — not introductory prices. If uninsured or uncovered, ask what month 4 costs, not month 1.
3. For brand-name medications, start with LillyDirect (Zepbound) or NovoCare (Wegovy) before going through a telehealth intermediary. You may get a better price direct.
4. For compounded options, verify the pharmacy is a named, state-licensed 503A facility. Ask whether pricing is flat across dose tiers or escalating.
5. For Medicare, ask your provider about the Bridge Program prior authorization pathway beginning July 2026. If you qualify, the $50/month co-pay is a genuine number.
6. Budget for at least a year. GLP-1 therapy is not a short-term intervention. The clinical evidence shows that most patients regain weight when they stop. The total cost of treatment is an annual — and potentially multi-year — consideration.

This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or adjusting any prescription medication.